Researchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones. By using an imaging ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and bone ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The addition of six cycles of radium-223 to first-line ...

XOFIGO® (radium-223 dichloride) in combination with enzalutamide significantly increased radiological progression-free survival (rPFS) for patients with metastatic castration-resistant prostate cancer ...

Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors Patients with bone metastatic CRPC ...

Adding radium-223 dichloride (Ra223) to metastasis-directed stereotactic ablative radiotherapy (SABR) did not improve progression-free survival compared with SABR alone in men with bone-only ...

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...

-- AR-V7 expression in CTCs isolated with TellDx is an independent negative prognostic factor in patients receiving radium-223 -- -- Study shows promise of CTCs and AR-V7 as biomarkers for radium-223 ...

RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men ...

Target lesion measurements in a 65-year-old metastatic castrate-resistant prostate cancer patient, 5 target lesions on b900 DWI, ADC (with green segmentation), T1-weighted and 18F-NaF PET/CT fusion, ...

ANDOVER, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- TellBio, Inc., a development-stage medical technology company focused on revolutionizing the detection of cancer metastasis through its unique and ...